TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

Next generation sequencing has identified somatic mutations that are prognostic of cancer. We evaluated the incidence and prognostic significance of somatic mutations in 89 MDS patients who received an allogeneic hematopoietic cell transplant. Next generation sequencing was performed on paraffin embedded bone marrow which was obtained at a median of 31 days prior to initiating the preparative regimen. The 3 most common subtypes of MDS were RAEB-1 (35%), RAEB-2 (29%) and RCMD (18%). Most patients (n=91%) received a myeloablative regimen of fludarabine plus intravenous busulfan.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 16, 2017 Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Rami S. Komrokji, Qing Zhang, Ambuj Kumar, Athanasios Tsalatsanis, Janelle Perkins, Taiga Nishihori, Teresa Field, Najla Al Ali, Asmita Mishra, David Sallman, Karma Z. Salem, Ling Zhang, Lynn Moscinski, Hugo F. Fernandez, Jeffre Tags: Original Study Source Type: research